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Landscape phageNanoencapsulation of anticancer drugs improves their therapeutic indices by virtue of the enhanced
permeation and retention effect which achieves passive targeting of nanoparticles in tumors. This
effect can be signiﬁcantly enhanced by active targeting of nanovehicles to tumors. Numerous
ligands have been proposed and used in various studies with peptides being considered attractive
alternatives to antibodies. This is further reinforced by the availability of peptide phage display
libraries which offer an unlimited reservoir of target-speciﬁc probes. In particular landscape phages
with multivalent display of target-speciﬁc peptides which enable the phage particle itself to become
a nanoplatform creates a paradigm for high throughput selection of nanoprobes setting the stage
for personalized cancer management. Despite its promise, this conjugate of combinatorial chemis-
try and nanotechnology has not made a signiﬁcant clinical impact in cancer management due to a
lack of using robust processes that facilitate scale-up and manufacturing. To this end we proposed
the use of phage fusion protein as the navigating modules of novel targeted nanomedicine plat-
forms which are described in this review.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Nano-encapsulated drugs (nanomedicines) offer a less toxic alter-
native for patients with cancer diseases. They reduce non-speciﬁc
drug delivery to normal tissues and deliver drugs to tumors [1–
3]. It is commonly believed that efﬁciency of nanomedicines can
be signiﬁcantly increased by their ligand-mediated targeting (LMT)
to cancer cells. While the potential beneﬁt of LMT was shown in
numerous experiments with animals [4–7], this technology has
not made a signiﬁcant clinical impact on cancer treatment [8,9].
The major challenge in translation of LMT into clinical develop-
ment has been the difﬁculty in developing targeted nanomedicines
with optimal biophysicochemical properties, biological behaviors,
and pharmacological proﬁles, while using robust processes that
facilitate scale-up and manufacturing.
Though most studies of nanomedicine targeting have used anti-
bodies, these therapies show limited efﬁcacy in solid tumorsmainly due to their large size (160 kDa) which precludes efﬁcient
penetration, a problem aggravated by the elevated tumor intersti-
tial pressure [10]. Furthermore, optimal tumor penetration may be
hindered by a high afﬁnity interaction between the antibody and
the ﬁrst few antigen molecules it comes in contact with thereby
preventing uniform diffusion, a phenomenon ﬁrst described as
‘‘binding site barrier’’ [11] and later demonstrated conclusively
[12]. Also, immunogenicity and non-speciﬁc uptake by the reticu-
lo-endothelial system contribute to a less than favorable clinical
outcome. Research has indicated that pharmacokinetic properties
are improved with the use of smaller ligands underscoring the
need for smaller molecules for tumor directed therapies [13]. Pep-
tides being in the range of 1–2 kDa and demonstrating acceptable
afﬁnity and speciﬁcity to their targets represent an attractive alter-
native to antibodies [14]. Much of the problems attendant with the
larger sized antibodies appears to be resolved with peptides. They
possess impressive tumor penetrating capacity, are generally not
recognized by the MPS and are less likely to instigate immune
responses. In addition, they exhibit a higher activity per mass
and greater stability [15]. The availability of combinatorial peptide
libraries from which potential tumor-speciﬁc ligands can be
extracted adds another dimension to the concept of peptide-tar-
geted nanomedicines. The use of phage displayed peptide libraries
for obtaining tumor-speciﬁc peptides and their application in tu-
mor-targeting has been illustrated with several examples in recent
reviews [14,16–18]. Liposomal targeting mediated by phage
display-derived peptides has been amply demonstrated [19–26].
Fig. 1. Electron micrograph of ﬁlamentous phage. Adapted from [105].
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chemistry required to attach the ligand to the liposomal surface.
Numerous covalent coupling techniques including the formation
of a disulﬁde bond, cross-linking between primary amines, reac-
tions between a carboxylic acid and primary amine, between
maleimide and thiol, between hydrazide and aldehyde or between
a primary amine and free aldehyde can be used (reviewed in
[27,28]). The conjugation procedures adapted from the armamen-
tarium of organic chemistry are quite efﬁcient for preparation of
various targeted liposomes in small scale – for their preliminary
laboratory and clinical study. However, the cost and reproducibil-
ity of these derivatives in quality and quantity sufﬁcient for phar-
maceutical applications are challenging problems. The use of the
conjugates may be less efﬁcient at the scaling step, when very
standardized and pharmaceutically acceptable preparations are re-
quired. For example, 2085 mg of lipid conjugated with single chain
antibody was obtained through a laborious procedure involving
high volume propagation of bacteria, several chromatographic
steps and sophisticated conjugation procedures yielding a prepara-
tion which had 93% purity [29]. Also, preparative conditions for the
addressed vesicles differ idiosyncratically from one targeted parti-
cle to another.
To facilitate the development and screening of targeted nan-
omedicines, signiﬁcant efforts has been made to develop methods
of high-throughput selection of cancer cell-binding phage proteins
and their self-assembly into nanovehicles [30]. These efforts re-
sulted in the development of several new targeted nanomedicine
platforms, which have been patented and proven using human
breast, prostate, pancreatic and lung cancer cells [30–43]. This re-
view describes these platforms, the key targeting components of
which are the tumor-speciﬁc major coat proteins preselected using
phage display technique.Fig. 2. Segment of landscape phage. Foreign peptides are pictured with white and
yellow atoms; their arrangement corresponds to the model of Marvin, 1994.
Adapted from [105].2. Phage display
Phage display technology emerged as a synergy of two funda-
mental concepts: combinatorial peptide libraries and fusion phage
[44]. The ﬁrst concept replaced the traditional collections of natu-
ral or individually synthesized compounds for libraries of peptides
obtained in parallel synthesis as grouped mixtures [45,46] (re-
viewed in [47]); the second—allowed displaying foreign peptides
on the surface of bacterial viruses (bacteriophages) as part of their
minor or major coat proteins [48,49] (reviewed in [44,50]). The
merge of these two concepts resulted in development of phage dis-
play libraries—multibillion clone compositions of self-ampliﬁed
and self-assembled biological particles [44].
Fusion phage, the fount of phage display technology, was ﬁrst
described by Smith [49] and involves modifying the phage genome
to achieve surface display of a peptide on the virion while main-
taining its viability and infectivity. Phage display has since then
evolved into a widely used screening resource for molecular tar-
gets supporting a burgeoning repertoire of applications [51–54].
The potential of phage display libraries is founded on phage biol-
ogy. Bacteriophages are viruses that infect bacteria and in particular
the phage vectors employed in phage display infect the bacterium
Escherichia coli. The ﬁlamentous phage of class Ff (M13, fd, and f1)
widely exploited to develop phage display systems possess single
stranded circular DNA enclosed in a tubular capsid composed pre-
dominantly of pVIII major coat protein with few copies of minor
coat proteins at the ends of the virion (Fig. 1). In-frame oligonucleo-
tide inserts into one of the coat protein genes results in the expres-
sion of the foreign amino acids as part of the corresponding coat
protein, creating a hybrid fusion protein displayed on the surface
of the phage particles. Thus, the extraneous peptide is now linked
to the phage genotype and this forms the cornerstone for thecreation of phage display libraries. Phage display libraries are cre-
ated by splicing unique randomized oligonucleotide inserts into
individual phages so that each phage displays a unique peptide.
Availability and amenability of numerous phage display vectors
has permitted the development of numerous phage display
systems [50]. One such system in particular, type 8, involves the
expression of a guest peptide on each copy of the major coat
protein pVIII of the phage particle. The intense iterative display
of peptides on the surface of the phage creates deﬁned organic
landscapes leading to the nomenclature, landscape phage (Fig 2).
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eign peptides, like in the traditional phage display approach, but
rather as a nanoparticle (nanotube) with emergent physico-chem-
ical characteristics determined by the speciﬁc landscapes formed
by the thousands of random peptides fused to the major coat pro-
tein pVIII [55]. Despite the extra burden, such particles could retain
their infectivity and progeny-forming ability making them a rich
source of selectable nanomaterials.
3. Landscape phage libraries
A landscape library is a multibillion-clone population of land-
scape phages with different structures. For example, landscape li-
braries f8/8 and f8/9 used in studies in our laboratory [56], were
constructed by splicing a degenerate coding sequence into the
beginning of the coat-protein gene in the vectors f8-1 and f8-6
[50], replacing wild-type codons 2–4 or 2–5, as shown below;where N is any nucleotide, and K is G or T. As a result, every protein
subunit in the landscape phage is ﬁve amino acids longer than in
the wild-type phage, and displays a ‘‘random’’ sequence of eight
or nine amino acids [55,56]. In any single clone, the random pep-
tide is the same in every particle, but almost every clone displays
a different random peptide. Landscape phages and their fusion pro-
teins have been shown to serve as substitute antibodies against
antigens and receptors, including live cancer cells [33,34,57–60].
The targeting protein can be obtained from the phage in a very
pure form in one step – using size exclusion chromatography, or
by extraction of the protein from phage by isopropanol–chloro-
form mixture.
The guest peptides in a landscape phage constitute up to 25% by
weight of the phage particle and overlays 50% of its surface. The
multivalent display of peptides, apart from contributing to avidity
allows for a greater freedom in manipulating the phage ﬁlament as
a scaffold for biospeciﬁc interactions. In fact, landscape phages
have been proposed as substitute antibodies with nanomolar and
subnanomolar afﬁnities and high speciﬁcity for protein and glyco-
protein antigens. When phage particles mimic antibodies many of
the intrinsic limitations of antibodies can be overcome. A culture of
cells secreting phages is an efﬁcient protein production system.
Phages are secreted from the cell nearly free of intracellular com-
ponents and can be puriﬁed by routine procedures. The phage
structure is robust and puriﬁed phage can be stored indeﬁnitely
without losing infectivity. These characteristics make landscape
phage libraries an ideal source for peptide ligands.
Landscape phage probes have been identiﬁed for a variety of
targets belonging to both the organic and inorganic realms and
encompassing a wide spectrum of complexity [30]. The process
of identifying phage probes is termed afﬁnity selection and a gen-
eric protocol for this procedure has been described in detail else-
where [33].
As a pertinent example, we successfully managed to isolate
highly speciﬁc and selective landscape phage probes for PC3 pros-
tate tumor cells. Further, we demonstrated that these probes could
be ﬂuorescently labeled and labeling does not adversely affect the
target association properties of the phage particles as evidenced by
ﬂuorescence microscopy and ﬂow cytometry [34]. This study
provided the proof of concept of using the landscape phage particle
itself as target-speciﬁc nanoparticles with diagnostic applications,
a fact that has already been proved with pIII display constructs
[61–65]. In addition, landscape phage have been used as diagnostic
probes for bacteria [66–68], spores [69], as components of genedelivery systems [70], biospeciﬁc adsorbents [71] and molecular
recognition interfaces in detection systems [72,73]. Phage derived
probes allow the fabrication of bioselective materials by self-
assemblage on metal, mineral or plastic surfaces [74–77]. These
observations led us to surmise the utility of derivatized phage
components as targeting moieties of drug carriers. In particular,
the pVIII major coat protein with the N-terminal guest peptide
has unique properties which qualify its use as a targeting ligand
for clinically important nanomedicines, such as PEGylated lipo-
somes, micelles and complexes with nucleic acids.4. Phage major coat protein pVIII
The ability of the major coat protein pVIII to associate with mi-
celles and liposomes emerges from its intrinsic function as a mem-
brane protein judged by its biological, chemical, and structuralproperties. During infection of the host E. coli, the phage coat is dis-
solved in the bacterial cytoplasmic membrane, while viral DNA en-
ters the cytoplasm [78]. The protein is synthesized in infected cell
as a water-soluble cytoplasmic precursor, which contains an addi-
tional leader sequence of 23 residues at its N-terminus. Prior to
assembly of viral progeny, precursor coat protein pVIII integrates
into inner membrane independently of the SEC translocation
machinery of the host bacterium. When this protein is inserted
into the membrane, the leader sequence is cleaved off by a leader
peptidase. Later, during the phage assembly, the newly synthe-
sized proteins are transferred from the membrane into the coat
of the emerging phage. Thus, the major coat protein can change
its conformation to accommodate various distinctly different
forms of the phage and its precursors: phage ﬁlament, intermedi-
ate particle and membrane-bound form. Despite this remarkable
adaptability, the coat protein contains only 50 amino acid residues.
It is very hydrophobic and insoluble in water when separated from
virus particles or membranes [79] (Fig. 3A). In virus particles it
forms a single, somewhat distorted a-helix with only the ﬁrst four
to ﬁve residues mobile and unstructured [80] (Fig. 3B). It is ar-
ranged in layers with a ﬁvefold rotational symmetry and approxi-
mate twofold screw symmetry around the ﬁlament axis, as shown
in Fig. 3C.
The structure of the major coat protein in the phage virions,
micelles and bilayer membranes is well resolved [81–83]. A vari-
ety of structural models for the protein in the membrane-bound
state have been proposed, with dominating I-shaped and L-shaped
structures, depending on the lipid model studied [81]. In dehy-
drated lipid bilayers and micelles, the 16-Å-long amphipathic
helix (residues 8–18) rests on the membrane surface in L-form,
while in hydrated lipids—a natural ‘stress-free’ environment it
extends from the lipid bilayer of liposomes as an I-form a-helix.
In liposomes, the 35-Å-long trans-membrane (TM) helix (residues
21–45) crosses the membrane at an angle of 26 up to residue
Lys40, where the helix tilt changes (Fig. 4). The helix tilt accom-
modates the thickness of the phospholipid bilayer, which is 31 Å
for the palmitoyl–oleoyl–phosphatidylcholine and palmitoyl–
oleoyl–phosphatidylglycerol—typical lipids of E. coli membrane
components. Tyr 21 and Phe 45 at the lipid–water interfaces
delimit the TM helix, while a half of N-terminal and the last C-ter-
minal amino acids, including the charged lysine side chains,
emerge from the membrane interior. The transmembrane and
amphipathic helices are connected by a short turn (Thr 19–Glu
20). In micelles having a curved surface, N-terminal domain of
NH2 COOH
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Fig. 3. pVIII phage major coat protein. (A) Schematic showing the primary structure and domain organization of the pVIII major coat protein in phage M13. (B) Three-
dimensional structure of pVIII coat protein showing its helical structure. White area corresponds to the position of the guest peptides. Yellow area shows segment that can be
randomized [106]. (C) Fragment of three-dimensional structure of landscape phage showing the arrangement of pVIII units. Adapted from [107].
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Fig. 4. The model of the pVIII protein in the lipid bilayer environment. Adapted
from [108].
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variety of protein shapes including L- and U-shapes in addition to
extended structures.
Spontaneous insertion of the major coat protein into lipid mem-
branes is believed to be mediated by interplay of electrophoretic
inﬂuences (membrane potential), electrostatic forces (charges on
membrane and protein) and hydrophobic interactions. The hydro-
phobicity of the transmembrane domain is chieﬂy responsible for
driving the insertion of the coat protein to allow for thermody-
namic equilibrium whereas the membrane potential and charges
on the protein in question are the major determinants of the topol-
ogy of the membrane associated protein [84,85]. The spontaneous
insertion of a membrane protein can be envisioned as a two-stepprocess. The ﬁrst step involves binding of the protein to the mem-
brane parallel to the plane of the membrane accompanied with
simultaneous insertion of the hydrophobic region into the hydro-
carbon core of the lipid bilayer (Fig. 5A). The second step would in-
volve the release of the hydrophilic tail into the trans side (Fig. 5B),
following probably the mechanisms characteristic for cell-pene-
trating peptides [86]. The structural characteristics of the mem-
brane-bound coat protein after spontaneous insertion was shown
to be predominantly a-helical [87]. Association of coat protein
with lipid vesicles has been determined by ﬂuorescence energy
transfer (FET) between the coat protein’s tyrosine and tryptophan
residues (donors) and a diphenylhexatriene (DPH) in the lipids
(acceptor). The membrane penetration of coat proteins depends
on the concentration of lipids available and almost complete asso-
ciation is seen at high lipid to protein ratios [84]. Furthermore, li-
pid membranes with negative charges demonstrate higher
amenability to spontaneous insertion whereas rigid lipid mem-
branes preclude spontaneous insertion. What is important to note,
coat protein insertion into liposomes follows an almost exclusive N
terminusout topological preference. A mutant of coat protein Pf3 of
the bacteriophage Pf3 having three additional leucine residues in
the transmembrane region and a complete replacement of charged
amino acids by asparagine (3L–4N) was shown to spontaneously
insert into lipid vesicles [88]. In an extension of this research, hy-
brid peptides comprising a fusion of a single IgG binding unit of
Staphylococcal protein A attached to the N-terminus of the coat
protein mutant was shown to spontaneously insert into liposomes
and resulted in an emergent liposomal property that of antibody
binding [89]. These observations formed the basis for our hypoth-
esis that target-speciﬁc phage fusion proteins would function as
liposomal and micelle ligands and targeting would improve the
performance of anticancer agents. The next two sections provide
a summary of studies undertaken to demonstrate the feasibility
of using tumor-speciﬁc phage fusion protein as navigating modules
for anticancer nanoparticles.
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Fig. 5. Spontaneous insertion of the major coat protein into lipid membranes. (A) In the ﬁrst step, the coat protein binds to the membrane parallel to the plane of the
membrane with the insertion of the hydrophobic region into the hydrocarbon core of the lipid bilayer. (B) In the second step, the hydrophilic tail is released into the trans side,
a process probably approximating the mode adopted by cell-penetrating peptides.
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Fig. 6. Phage fusion protein-targeted nanoparticles. Target-speciﬁc phage fusion
protein selected from phage libraries can be introduced into drug-loaded PEGylated
liposomes exploiting their intrinsic propensity to spontaneously integrate into the
lipid bilayers. Explanation in the text. Adapted from CNRS international magazine,
 F. Caillaud/CNRS Photothèque/SAGASCIENCE.
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The unique characteristics of phage major coat protein and its
recombinant fusion variants allows their use for development of
targeted anticancer nanomedicines. This novel approach exploits
the intrinsic membrane properties of the phage major coat protein,
i.e., its propensity to reside in the bacterial internal membrane dur-
ing phage infection and ability to spontaneously integrate into the
lipid bilayer in vitro. The phage speciﬁc for the target organ, tissue
or cell is selected from the multibillion clone landscape phage
libraries [34,57,59,60,70,90], its pVIII coat protein isolated and
inserted into liposomes or micelles, as exempliﬁed below.
Individual proteins or a mixture of targeted phage proteins can
be introduced into the preformed PEGylated doxorubicin-loaded
liposomes, such as commercially available Doxil (Caelyx, Lipo-
dox) (Fig. 6) by their incubation with the cholate-stabilized phage
fusion protein. The crude formulation is dialyzed and the cholate-
free liposomes are puriﬁed by size-exclusion chromatography. The
following properties of the targeted liposomes are controlled: (a)
liposome morphology, size and size distribution; (b) content of
encapsulated drug; (c) presence and orientation of inserted fusion
proteins; (d) liposome ability to keep entrapped prototype drugs
and reporter protein moieties both in water solutions and in blood
plasma; (e) speciﬁc binding activity of the phage protein-bearing
liposomes; (f) cytotoxic activity of the targeted nanomedicines to-
wards the target cancer cells in vitro and in vivo.
A major concern, in initial studies, related to the ability of the
fusion protein to penetrate through the polyethylene glycol (PEG)crown surrounding the liposomes. PEG as an inert, biocompatible
polymer forms a protective layer over the liposome surface that
masks surface charge, increase the hydrophilicity of liposomes,
slows down liposome clearance by opsonins, inhibits destruction
of liposomes by lipoproteins and increases their bioavailability
[2,91].
Reiterating the earlier discussion, the hydrophobic C-terminal
domain of the major coat protein and its fusion forms accommo-
date perfectly well in the micelles and liposomes formed by natu-
ral phospholipids. Existing structural data suggest that the
amphiphilic and hinge domains of the major coat protein may also
accommodate well in the random coiled corona of the PEGylated
vesicles, displaying the fusion peptides on their surface. Since data
on the exact random coil conformation of the PEG moieties are
quite sparse [26,92], we elucidated a true conformation of the
phage proteins in PEGylated vesicles in a model experiment using
streptavidin-coated gold beads as a model target and the major
coat protein with a fused streptavidin binding peptide as a target-
ing ligand [36]. The translation of the peptide speciﬁcity for strep-
tavidin to the liposomes was evidenced by a functional test
utilizing streptavidin-conjugated colloidal gold nanoparticles. As
Fig. 7 aptly demonstrates, targeted liposomes show a clear propen-
sity to have the streptavidin-conjugated colloidal gold particles
studded on their shell as against control liposomes. To determine
protein topology in the lipid membrane and prove the display of
the binding peptides on the crown of the PEGylated nanoparticles,
the protein-modiﬁed liposomes were treated ﬁrst with proteinase
K and then analyzed by Western blot probed for the presence of
the N-terminal and C-terminal protein sequences, using N- and
C-terminus-speciﬁc antibodies. Based on these model experiments
it was concluded that the target-speciﬁc peptide fused to the major
coat protein is exposed on the PEG crown of the drug-loaded ves-
icle. In following experiments it was demonstrated that the speci-
ﬁcity of phage proteins towards cancer cells translates to the
protein-modiﬁed nanomedicines, increasing their speciﬁc binding
and cytotoxic activity towards the target cancer cells. It was dem-
onstrated that the phage major coat proteins fused to cancer cell-
targeting peptides can serve as an anchor for association of these
peptides with drug-loaded liposomes and micelles without
destruction of their integrity. Targeting peptides are exposed and
allow for speciﬁc binding of drug-loaded phage-nanoparticles to
cancer cells [35,38,43].
Following conclusive proof of concept studies for using phage
fusion protein as a simple and cost-effective means for preparing
tumor-targeted liposomes, Wang et al. undertook studies to opti-
mize phage liposome preparative conditions that would maximize
their targeting efﬁcacy. Accordingly, a factorial design approach
was used to determine the role of preparative protocol, phage
Fig. 7. Functional test for targeted liposomes with streptavidin conjugated colloidal gold nano-particles. Targeted liposomes prepared by co-incubation of puriﬁed major coat
protein speciﬁc for streptavidin and DOXIL were tested using streptavidin conjugated colloidal gold particles for the speciﬁcity and functionality of the incorporated phage
coat protein. (A) Targeted liposomes studded with streptavidin conjugated colloidal gold particles with a particle to liposome ratio of 1.8. (B) Non-targeted liposomes
subjected to the same assay with a particle to liposome ratio of 0.09. Adapted from [36].
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on the targeting efﬁciency of the phage liposomes. Results indi-
cated that a speciﬁc lipid cocktail of ePC:CHOL:DPPG:DOTAP:-
PEG2K-PE:45:30:20:2:3 with 0.5% phage fusion protein had the
most positive effect on the targeting speciﬁcity of the phage lipo-
somes. Furthermore, the post-insertion protocol wherein the fu-
sion protein is inserted into fully formed liposomes produced
formulations which were more uniform and stable than the direct
incorporation approach wherein the fusion protein is added at the
time of liposome formation [39]. In another study using liposomes
modiﬁed with MCF-7-speciﬁc phage fusion protein [57], Wang
et al. demonstrated that the targeting speciﬁcity of modiﬁed lipo-
somes was solely due to the presence of the tumor-speciﬁc peptide
on the N-terminus of the phage fusion protein in the liposomal bi-
layer. Removal of this binding peptide by proteolytic treatment,
substitution of this peptide with a random-peptide or the presence
of free peptide in the assay abolished the speciﬁc interaction be-
tween the modiﬁed liposomes and their target MCF-7 cells [40].
Results obtained from liposomal studies were also translatable to
other nanoparticles like micelles. Thus, paclitaxel containing mi-
celles targeted with phage fusion protein speciﬁc for MCF-7 cells
showed preferential binding to their cognate target cells as com-
pared to non-target cells resulting in a signiﬁcantly higher cytotox-
icity towards target MCF-7 cells than free drug or non-targeted
micelle formulations. This differential toxicity was not seen in
non-target C166 cells leading the authors to surmise that cancer
cell-speciﬁc phage proteins identiﬁed from phage display peptide
libraries can serve as a ‘‘substitute antibody’’ for polymeric mi-
celle-based pharmaceutical preparations [41,42].
In contrast to the sophisticated and poorly controllable conju-
gation procedures used for coupling of peptides and antibodies to
the targeted vesicles, the new landscape phage-based approach re-
lies on and mimics the extremely precise natural mechanisms of
biosynthesis and self-assembly of phage particles. When landscape
phage libraries serve as a reservoir of the targeted membrane pro-
teins one of the most troublesome steps of the conjugation tech-
nology is bypassed. Furthermore, it does not require idiosyncratic
reactions with any new shell-decorating polymer or targeting li-
gand and may be easily adapted to a new liposome or micelle com-
position and a new addressed target. No re-engineering of the
selected phage is required at all: the phages themselves serve as
the source of the ﬁnal product—coat protein genetically fused to
the targeting peptide.
6. Phage fusion protein-mediated delivery of anticancer siRNA
Synthetic small fragments of RNA are known to inhibit speciﬁc
protein expression by suppressing target genes at the mRNA level,
amechanismdescribed as RNA interference (RNAi). High speciﬁcity,high efﬁciency, and low toxicity have made these small interfering
RNA (siRNA) popular as potential anticancer agents. However, deliv-
ery of siRNA into the cells remains challenging due to their instabil-
ity in physiological ﬂuids as well as their inability to cross cell
membranes to achieve intracellular accumulation at the site of ac-
tion [93]. For these reasons, other mechanisms to deliver siRNA to
target cells have been devised that include viral and bacterial deliv-
ery, the use of liposomes or nanoparticles, and stabilization of siRNA
by chemical modiﬁcation [94]. Despite some improvement in the
bioavailability, many siRNA-carrier systems, including cationic
polymers and lipids, suffer from inherent deﬁciencies associated
with poor cellular delivery mainly due to rapid uptake into tissues
of phagocytic systems [95–97]. PEGylated (‘stealth’) liposomes re-
main the ideal choice of carrier for siRNA delivery mainly due to
their biological inertness, non-toxicity and protection from nucle-
ase degradation [98]. Further improvements to the efﬁcacy of deliv-
ery can be achieved if the liposomal vehicles of siRNA can be
speciﬁcally targeted to tumor cells by conjugation with targeting li-
gands [99]. For example, siRNA-loaded immunoliposomes targeted
with anti-transferrin antibody produced speciﬁc inhibition of Her-2
expression in breast cancer animalmodel and tumor growth inhibi-
tion in pancreatic cancer animal model [100]. Attachment of cell-
penetrating peptides (CPP), a family of peptides able to translocate
across the cell membrane, have also been used to deliver siRNA into
cancer cells [101]. It was shown that liposomes bearing a synthetic
arginine-rich CPP are stable and can efﬁciently transfect lung tumor
cells in vitro. Recent study has shown that systemic delivery of
siRNA encapsulated in targeted liposomes can efﬁciently silence
oncogenes in metastatic tumor cells [102]. Taken together, siRNA-
containing targeted liposomes represent a promising treatment
avenue for cancer. However, the drawbacks in the production of tar-
geted liposomal preparations as outlined in the previous section led
us to consider phage proteins as easily available targeting compo-
nents of the siRNA-loaded liposomal vehicles.
Bedi et al. described a new strategy for targeted siRNA delivery
using phage fusion proteins as navigating modules for liposomes.
The targeted siRNA liposomes were produced by a novel approach
in which two different parental liposomes, one containing sponta-
neously inserted siRNA and the other containing fusion phage pro-
teins are fused together to obtain the ﬁnal therapeutic formulation
[32]. For conceptual studies, the PRDM14 gene – a member of the
family of genes that encode proline rich domain proteins (PRDM),
was chosen as a target for siRNA-mediated silencing because it has
been suggested to play an important role in carcinogenesis [103].
MCF-7 speciﬁc phage protein DMPGTVLP (here and later fusion
phages and their proteins will be designated by the sequence of
inserted foreign peptides) was derived from landscape phage
libraries and has already been described in previous sections and
publications as targeting ligands for drug-loaded liposomes
siRNA
+
Cholate micelles
Phage protein
Fig. 8. Phage like nanoparticles or nanophage formed by mixing of cholate
solubilized phage fusion protein with siRNA with the gradual removal of cholate.
N-terminus of phage protein is the targeting ligand whereas positively charged C-
terminal end of the major coat protein interacts with negatively charged phosphate
groups of siRNA. Adapted from [31].
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had to adapt a novel three-step approach in lieu of the afore-men-
tioned simplistic approach as the spontaneous insertion of RNA
and phage fusion protein into pre-formed liposome follow
different mechanistic principles. First, siRNAs was inserted into a
liposome formed by a mixture of neutral and positively charged
lipids (plus-liposome). This liposome has a positively charged
interface that attracts the negatively charged siRNAs and drives
their internalization [104]. Second, the fusion phage protein
(DMPGTVLP) was inserted into a liposome formed by neutral and
negatively charged lipids (minus-liposome). This liposome has a
negatively charged interface that attracts C termini of the major
coat protein, drives their translocation through the lipid bilayer
and allows their anchoring at the internal liposomal interface, as
was studied before [84]. Third, the plus liposomes loaded with siR-
NAs and minus liposome loaded with phage protein were fused to-
gether to integrate into the protein-targeted particles containing
siRNA. MCF-7 cells treated with siRNA–protein liposomes showed
a signiﬁcant down-regulation of the PRDM14 gene expression as
compared to the cells treated with control liposomal preparations
that included the plus- and minus-liposomes by themselves as
well as plain liposomes. The level of down-regulation was compa-
rable to that achieved by a complex of siRNA with lipofectamine, a
‘gold standard’, although toxic carrier for siRNAs. These results
were further supported by western blot analysis that revealed that
PRDM14 protein expression was diminished in cells treated with
siRNA–DMPGTVLP phage protein liposomes.
In an elegant extension of this concept, Bedi et al. undertook
studies to evaluate the direct use of fusion phage proteins as nano-
carriers of siRNA [31]. The basis of their approach was the premise
that phage coat proteins act as natural vehicles for phage genetic
material during phage life cycle; encapsulating the nucleic acid
after its production, conveying the same to the host cells and then
releasing the genetic payload at the host cell membrane for further
propagation. Thus, phage fusion proteins could and would act as
natural vehicles for small fragments of nucleic acids like siRNA
(Fig. 8). Accordingly, MCF-7-speciﬁc phage fusion proteins were
incubated with GAPDH siRNA to form particles, called ‘‘phagelike
nanoparticles’’ or ‘‘nanophages’’. These entities, seen as small par-
ticles of diameter 11 nm, protected the siRNA from degradation by
serum nucleases, retained the target-binding ability of the fusion
phage protein and were able to deliver a siRNA payload to the
target cells to achieve knockdown of the GAPDH gene. Thus, nano-
phages may represent a very attractive formulation for delivery of
therapeutic siRNA into tumors.
7. Conclusions
Filamentous bacteriophages, viruses that infect bacteria, are in
many ways ideal nanomaterials. Their structure and infection cycle
are encoded in small genomes that can be readily manipulatedusing simple recombinant DNA techniques. They have well-deﬁned
geometry and uniformity favorable for nano-fabrication. Moreover,
they have turned out to be remarkably tolerant of structural
alteration. The atomic structures of ﬁlamentous phages and their
component proteins have been determined, allowing precise
engineering of their modiﬁed forms with predetermined shapes
and functions and a precise spatial distribution of fused functional
peptides at a nanoscale level.
Phage nanobiotechnology has evolved from phage display, a
suite of techniques for surveying vast populations of peptides for
rare structures with some desired target behavior. The surveys
are accomplished by selective strategies that exploit the ability
to display phage-encoded peptides on the outer virion surface by
genetic fusion to phage coat proteins. The phage libraries that
are the initial input to selection can comprise billions of distinct
phage clones, displaying billions of distinct peptides. The most
common of survey strategy is afﬁnity selection, which enriches
for phage whose displayed peptides bind an immobilized selector.
The selector can be a conventional biomolecule such as an anti-
body or receptor, or it can be a complex biological structure such
as whole cells in culture or whole tissues in living animals. In most
phage display applications, the desired end-product is the dis-
played peptide; the virion serves only a vehicle for discovery. In
phage nanotechnology, in contrast, it is the entire phage proteins
or ensembles of proteins and virion that is the goal of discovery.
In summary, it is in the ability to select nanomaterials with favor-
able behavior from vast initial nanomaterial libraries that phage
nanotechnology differs most dramatically from other modes of
nanotechnology.
New modes of peptide display designed to modify the proper-
ties of the entire virion have come recently to the fore. In ‘‘land-
scape’’ libraries, described in this review, almost a quarter of the
virion’s surface area differs from one phage clone to another. These
creative developments have already paid off in contributions to
multiple areas of medicine and technology, including medical diag-
nostics and monitoring, molecular imaging, targeted drug and gene
delivery, vaccine development, and bone and tissue repair. We
hope that the assembling in this review recent achievements in
targeted drug delivery using phage nanotechnology will help the
members of the growing community of phage bioengineers stay
abreast of recent trends and inspire them to create new ones. Fur-
ther advances in these areas will require the collective efforts of
specialists in diverse ﬁelds—medical doctors, microbiologists,
structural biologists, chemists, pharmacologists, and many others.
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